Diabetes

Most experts recommend adding basal insulin, but basalization has its limits controlling glucose in type 2 diabetes.

Patients who were seen at an emergency department had an increased likelihood of diabetic ketoacidosis during the next 14 days.

There are no guidelines to help physicians choose insole stiffness for patients with diabetes.

Top news of the day from across the health care landscape.

Drug interactions can affect the pharmacokinetics or pharmacodynamics of diabetes medications, causing decreased efficacy or increased toxicity.

Teenagers face cognitive, social, and psychological pressures that can interfere with successful diabetes management.

The creation of novel investigational drugs that target a protein receptor found in fat tissue could pave the way for better treatments for type 2 diabetes.

Active ingredients in chili peppers and cannabis help subside gut inflammation, and could lead to new therapies for diabetes and colitis.

Metformin may treat Fragile X syndrome.

Vitamin A and a high-fat diet could lead to a high body mass index.

As the prevalence of diabetes continues to rise, the development of safer and more efficient therapeutics is increasing in importance.

Targeting a protein receptor in body fat shows promise in attacking diabetes.

Children with obesity may be 4 times more likely to develop type 2 diabetes.

Cardiovascular disease among diabetes patients drops through coordinated healthcare.

FDA issues safety warning for canagliflozin in the treatment of type 2 diabetes.

Canagliflozin (Invokana) may increase the risk of leg and foot amputations in patients with type 2 diabetes.

Top news of the day from across the health care landscape.

Pharmacists can help patients with diabetes manage glucose control.

Adherence to diabetes therapy related to the high cost of treatment.

Research demonstrates that pharmacists can make a difference for patients with diabetes.

Postbiotics observed to reduce blood glucose levels and increase insulin sensitivity in patients with diabetes.

Nonadherence in patients with diabetes adversely affects glycemic control.

How many patients does the average community pharmacist see who are nonadherent because they can't afford their medications?

Study weighs whether aflibercept (Eylea) is cost-effective compared with ranibizumab (Lucentis) in treating diabetic macular edema.

The FDA has approved an expanded indication for Tresiba to improve glycemic control in patients with diabetes as young as 1 year.